{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.70","upperLimit":"0.80","value":"0.76"},{"groupId":"OG001","lowerLimit":"0.72","upperLimit":"0.81","value":"0.77"}]}],"title":"1 year (12 months)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.46","upperLimit":"0.58","value":"0.52"},{"groupId":"OG001","lowerLimit":"0.46","upperLimit":"0.58","value":"0.52"}]}],"title":"2 years (24 months)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.34","upperLimit":"0.46","value":"0.40"},{"groupId":"OG001","lowerLimit":"0.31","upperLimit":"0.43","value":"0.37"}]}],"title":"3 years (36 months)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"301"},{"groupId":"OG001","value":"297"}],"units":"Participants"}],"description":"The probability that survival time is at least 1, 2, or 3 years was summarized using Kaplan-Meier estimates.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants were treated with Pemetrexed plus Cisplatin and concurrent TRT (\"Concurrent Phase\") for three 21-day cycles, followed by a 3-5 week \"Recovery Period,\" then treated with consolidation chemotherapy with pemetrexed (\"Consolidation Phase\") for up to four 21-day cycles\n\nConcurrent Phase:\n\nPemetrexed: 500 mg/m\\^2, IV on Day 1 of each 21-day cycle for 3 cycles. Cisplatin: 75 mg/m\\^2, IV on Day 1 of each 21-day cycle x 3 cycles. TRT: Beginning on Day 1 of chemotherapy, once daily fractions (2 Gy per day), 5 days a week for 6 weeks and 3 days to target 66 Gy in 33 fractions.\n\nConsolidation Phase:\n\nPemetrexed: 500 mg/m\\^2, IV on Day 1 of each 21-day cycle up to 4 cycles","id":"OG000","title":"Arm A: Pemetrexed + Cisplatin and TRT"},{"description":"Participants were treated with Etoposide plus Cisplatin and concurrent TRT (\"Concurrent Phase\") for two 28-day cycles, followed by a 3-5 week \"Recovery Period,\" then received consolidation treatment with cytotoxic chemotherapy of choice (\"Consolidation Phase\") for up to 2 cycles\n\nConcurrent Phase:\n\nEtoposide/Cisplatin (28-day cycle); Etoposide: 50 mg/m\\^2, IV on Days 1 to 5 and Days 29 to 33 and Cisplatin: 50 mg/m\\^2, IV on Days1, 8, 29, and 36\n\nConsolidation Phase options:\n\nOption 1: Continue the same treatment plan as Concurrent Phase Option 2: Vinorelbine/Cisplatin (21-day cycle); Vinorelbine: 30 mg/m\\^2, IV on Days 1, 8, 22, and 29; Cisplatin: 75 mg/m\\^2, IV on Days 1 and 22 Option 3: Paclitaxel/Carboplatin (21-day cycle); Paclitaxel: 200 mg/m\\^2, IV, on Days 1 and 22; Carboplatin: area under the concentration-time curve (AUC) = 6 (Carboplatin dosing based on calculated creatinine clearance), IV on Days 1 and 22","id":"OG001","title":"Arm B: Etoposide + Cisplatin and TRT"}],"paramType":"NUMBER","populationDescription":"All randomized participants. Arm A had 124 participants censored and Arm B had 117 participants censored.","reportingStatus":"POSTED","timeFrame":"Baseline to Date of Death from Any Cause (Up to 71.4 Months)","title":"Survival Rates at 1, 2, and 3 Years","type":"SECONDARY","unitOfMeasure":"probability of survival"}